USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

The CRL did not identify any outstanding scientific issues with the product.

CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Biocon Biologics insulins facility in Malaysia receives EU GMP Certification

The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.

Merck and the Bill & Melinda Gates Medical Research Institute announce licensing agreement for tuberculosis antibiotic candidates

The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.

Biocon Biologics signs licensing agreement with Yoshindo

Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics

Jacobio Pharma to collaborate with Merck on clinical trial of JAB-21822

This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

Panacea Biotec bags US $127.30 mn for supply of Pentavalent Vaccine

UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027

Biocon Foundation receives Mahatma Award 2022

The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities

BioMarin simplifies organizational structure to increase efficiency

The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023

AGC begins study to expand its Bio-CDMO capability in Japan